Survival impact of optimal treatment for elderly patients with colorectal cancer: A real world study

Basit Öğe Kaydı
dc.authorid0000-0002-4597-9721en_US
dc.authorid0000-0001-7336-871Xen_US
dc.authorid0000-0003-0882-0524en_US
dc.authorid0000-0003-3878-988Xen_US
dc.authorid0000-0003-4122-8389en_US
dc.authorid0000-0002-7140-8957en_US
dc.authorid0000-0002-7451-2786en_US
dc.contributor.authorAkdeniz, Nadiye
dc.contributor.authorKüçüköner, Mehmet
dc.contributor.authorKaplan, Muhammet A.
dc.contributor.authorUrakçı, Zuhat
dc.contributor.authorSezgin, Yasin
dc.contributor.authorKarhan, Oğur
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.date.accessioned2023-03-15T11:07:39Z
dc.date.available2023-03-15T11:07:39Z
dc.date.issued2021en_US
dc.departmentDicle Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Medikal Onkoloji Ana Bilim Dalıen_US
dc.description.abstractBackground: In this real-life practice study, we aimed to find whether elderly colorectal cancer (CRC) patients in our center were treated optimally and also if this has an effect on overall survival (OS) or not. Methods: We have retrospectively screened 150 CRC patients older than 65 years, diagnosed in our institution between 2010 and 2018. As study variables, patient characteristics, tumor location, tumor, nodes, metastases stage, Eastern Cooperative Oncology Group performance status (ECOG PS), comorbidities, adjuvant or metastatic chemotherapy regimens, and treatment toxicity were recorded, and the OS rate of patients was assessed. Results: The median age was 72 (range 65 - 89) years and 48 (32%) patients had metastatic disease at the time of diagnosis. The median OS (mOS) in the suboptimal adjuvant treatment group was 31.5 (range 20.7-42.3) months, whereas mOS was not reached during the median follow-up time in the optimal treatment group (P = 0.036). The addition of oxaliplatin to chemotherapy had no benefit on mOS (P = 0.318). In the metastatic setting, the mOS in the optimal and suboptimal treatment group was 27.2 (range 10.7-43.7) months and 13.4 (range 7.5-18.8) months respectively, and was statistically significant (P = 0.001). Conclusion: Our study revealed that optimal treatment had a significant effect on the mOS of elderly CRC patients and it was well tolerated. Advanced age alone is not a sufficient parameter for precluding effective therapy in elderly patients with CRC.en_US
dc.identifier.citationAkdeniz, N., Küçüköner, M., Kaplan, M.A., Urakçı, Z., Sezgin, Y., Karhan, O. ve diğerleri. (2021). Survival impact of optimal treatment for elderly patients with colorectal cancer: A real world study. Indian Journal of Cancer, 58(4), 539-544.en_US
dc.identifier.doi10.4103/ijc.IJC_409_19
dc.identifier.endpage544en_US
dc.identifier.issn0019-509X
dc.identifier.issn1998-4774
dc.identifier.issue4en_US
dc.identifier.pmid34380826
dc.identifier.scopus2-s2.0-85122654610
dc.identifier.scopusqualityQ3
dc.identifier.startpage539en_US
dc.identifier.urihttps://hdl.handle.net/11468/11396
dc.identifier.volume58en_US
dc.identifier.wosWOS:000756790600009
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAkdeniz, Nadiye
dc.institutionauthorKüçüköner, Mehmet
dc.institutionauthorKaplan, Muhammet Ali
dc.institutionauthorUrakçı, Zuhat
dc.institutionauthorSezgin, Yasin
dc.institutionauthorKarhan, Oğur
dc.institutionauthorIşıkdoğan, Abdurrahman
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofIndian Journal of Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectColorectal canceren_US
dc.subjectElderly patienten_US
dc.subjectOptimal treatmenten_US
dc.titleSurvival impact of optimal treatment for elderly patients with colorectal cancer: A real world studyen_US
dc.titleSurvival impact of optimal treatment for elderly patients with colorectal cancer: A real world study
dc.typeArticleen_US

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
[ X ]
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu